Faced with disruptive economic, demographic and technological change, most insurers are struggling to reinvent their organizations for the future. According to Empowered for the future: Insurance...

Gartner Security and Risk Summit 2016 -- Fasoo, Inc., the leader in Data and Software Security, today released the results of the security industry's first look at organizations' confidence around...

Sanofi announced today the presentation of the results of the pivotal Phase 3 LixiLan-O and LixiLan-L clinical trials with the investigational titratable fixed-ratio combination of basal insulin...

New data from a completed Phase 3 trial show Trulicity® (dulaglutide) 1.5 mg significantly reduced hemoglobin A1c (A1C) and body weight as an add-on to insulin glargine without increasing the...

New analyses showed risk reductions were consistent across age groups for cardiovascular (CV) outcomes, including CV death, with Jardiance® (empagliflozin) compared with placebo when added to...

Industry leaders, developers and researchers at the American Diabetes Association's 76th Scientific Sessions are demonstrating how they are tapping into Watson cognitive computing to transform the...

Cambridge, UK: Kicking off London Tech Week 2016, Linguisticator and Macunx VR will host an unforgettable evening focused on the potential of VR, AR and mixed reality in education, life sciences...

An interim analysis of registry data evaluating therapeutic response to neurostimulation from a device for treating cluster headaches demonstrates the effectiveness of the therapy and was...

Results from the MARLINA-T2D™ trial demonstrated that Tradjenta® (linagliptin), which is marketed by Boehringer Ingelheim and Eli Lilly and Company (NYSE: LLY), reduced blood sugar in adults...

VeroScience LLC, is pleased to announce that independent research conducted by Dr. Ralph DeFronzo and his team at UT Health Science Center at San Antonio ("Health Science Center") has continued to...